Specialised Therapeutics secured the rights to NIKTIMVO in Australia, New Zealand, and Singapore via a June 2025 agreement with Incyte. The company said it is exploring reimbursement through the Pharmaceutical Benefits Scheme.
Australia approves first in class therapy for chronic graft versus host disease
May 5, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
This unique historical oddity says all we need to know about the institution
May 26, 2026 - - Latest News -
New Zealand's Pharmac consulting on new vaccine brands and wider flu access for young children
May 26, 2026 - - Latest News -
New national survey reveals muscle health screening gap in Australian general practice
May 26, 2026 - - Latest News -
Mayne Pharma awarded legal costs as business expansion gains momentum
May 25, 2026 - - Latest News -
The risk to patients of this institution getting too close to the sun
May 25, 2026 - - Latest News -
Pharmacy Guild urges immediate funding for pharmacy to vaccinate in response to outbreak
May 24, 2026 - - Latest News -
AusBiotech launches survey in response to Budget’s 'blind spot' on R&D impact
May 24, 2026 - - Australian Biotech
